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Abstract
Objective: We conducted a mixed-methods study to examine serodiscordant and seroconcordant (HIV-positive/HIVpositive) male couples’ PrEP awareness, concerns regarding health care providers offering PrEP to the community, and
correlates of PrEP uptake by the HIV-negative member of the couple.
Design: Qualitative sub-study included one-on-one interviews to gain a deeper understanding of participants’ awareness of
and experiences with PrEP and concerns regarding health care providers offering PrEP to men who have sex with men
(MSM). Quantitative analyses consisted of a cross-sectional study in which participants were asked about the likelihood of
PrEP uptake by the HIV-negative member of the couple and level of agreement with health care providers offering PrEP to
anyone requesting it.
Methods: We used multivariable regression to examine associations between PrEP questions and covariates of interest and
employed an inductive approach to identify key qualitative themes.
Results: Among 328 men (164 couples), 62% had heard about PrEP, but approximately one-quarter were mistaking it with
post-exposure prophylaxis. The majority of participants had low endorsement of PrEP uptake and 40% were uncertain if
health care providers should offer PrEP to anyone requesting it. Qualitative interviews with 32 men suggest that this
uncertainty likely stems from concerns regarding increased risk compensation. Likelihood of future PrEP uptake by the HIVnegative member of the couple was positively associated with unprotected insertive anal intercourse but negatively
correlated with unprotected receptive anal intercourse.
Conclusions: Findings suggest that those at greatest risk may not be receptive of PrEP. Those who engage in moderate risk
express more interest in PrEP; however, many voice concerns of increased risk behavior in tandem with PrEP use. Results
indicate a need for further education of MSM communities and the need to determine appropriate populations in which
PrEP can have the highest impact.
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populations [1,3,4]; however, the FEM-PrEP and two arms of
the VOICE trials have been stopped for futility [5,6,7].
Despite these promising results, MSM communities continue to
have ambivalence and concerns about PrEP. Prior studies have
examined the knowledge of and attitudes toward PrEP use
[8,9,10,11]; however, due to the novelty of PrEP, many questions
regarding the acceptability and adoption of PrEP within the MSM
community and correlates of PrEP uptake remain unanswered.
Serodiscordant couples represent an important target group for
PrEP, thus it is important to understand perceptions and attitudes
of both HIV-negative and HIV-positive partners towards PrEP as
such understanding will contribute to optimizing uptake when
PrEP becomes available.

Introduction
The use of HIV antiretroviral (ARV) medications by HIV
uninfected individuals to reduce risk of HIV infection prior to
engaging in high risk behavior, also known as HIV-1 pre-exposure
prophylaxis (PrEP), has been shown to be effective in four clinical
trials to date [1,2,3,4]. The seminal PrEP trial, iPrEx, revealed that
tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) can
reduce the risk of HIV in men who have sex with men (MSM)
and transgender women at high risk for HIV infection by 44% [2].
The Partners PrEP, TDF2, and CAPRISA004 studies have
revealed further evidence of the efficacy of PrEP in other
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While PrEP has high potential as a biomedical HIV prevention
intervention strategy [12,13,14,15], effective policies and programs
to support PrEP will require the input of MSM communities.
Moreover, the approval of TDF/FTC as HIV-1 PrEP by the Food
and Drug Administration intensifies the need for knowledge about
PrEP awareness, use, and potential barriers to its success. To
address gaps in knowledge, we conducted a mixed-methods study
to examine the awareness of PrEP to prevent HIV infection,
concerns regarding offering PrEP to the community, and
correlates of future intentions for PrEP uptake by HIV-negative
individuals. Our quantitative approach consisted of a crosssectional study of HIV serodiscordant and seroconcordant (HIVpositive/HIV-positive) male couples to explore awareness of the
existence of PrEP and examine the correlates of the participant’s
or the participant’s partner’s likelihood of PrEP uptake in the
future and the level of agreement with the notion of health care
providers offering PrEP to anyone who requests it. Qualitative
interviews were conducted with a subsample of serodiscordant and
seroconcordant couples to gain a deeper understanding of
participants’ knowledge of PrEP, personal experiences with PrEP,
and perspectives regarding offering PrEP to the community.

Data Collection
Data collection for quantitative survey. To minimize
partial couple’s data (i.e., obtaining data from one member of
the couple only), we required couples to attend assessment
appointments together, but they were separated during the
consenting process and data collection to avoid the possibility of
shared responses or potential partner coercion. Data were
collected with a combination of Computer Assisted Personal
Interviewing (CAPI) and Audio Computer Assisted Self Interviewing (ACASI) procedures.
The PrEP questionnaire was included in the Duo Project
questionnaire starting April 2011 and assessed participants’
awareness of the existence of PrEP; the sources of their
information regarding PrEP; and prior use of PrEP by self,
partner, or acquaintance. Participants were initially asked if they
had heard of PrEP or the iPrEX study and PrEP was defined as
‘‘HIV-negative people taking HIV medications to try to reduce
their chances of becoming infected with HIV.’’ Three key PrEP
questions, PrEP1, PrEP2, and PrEP3, were asked in quantitative
surveys. PrEP1 asked ‘‘How likely is it that your partner would use
PrEP in the future?’’ This question was only asked from
participants whose partners were HIV-negative and responses
ranged from 0: ‘‘not at all likely’’ to 9: ‘‘extremely likely’’. The
HIV-negative individuals’ likelihood of taking PrEP in the future
was asked by PrEP2: ‘‘How likely is it that you would use PrEP in
the future?’’ Responses ranged from 0: ‘‘not at all likely’’ to 9:
‘‘extremely likely’’. Lastly, PrEP3 was asked of all participants and
assessed participants’ level of agreement with offering PrEP: ‘‘How
much do you agree or disagree with the following statement: ‘PrEP
should be offered to anyone who wants to take it’.’’ With responses
ranging from 1: ‘‘strongly disagree’’ to 5: ‘‘strongly agree’’.
Other information collected on participants included demographics (age, race/ethnicity, sexual orientation, education, and
income); depression (assessed using the Center for Epidemiologic
Studies Depression (CES-D) scale); length of time together as a
couple; sexual behavior (report of unprotected insertive/receptive
anal intercourse with primary or other partner) in the past three
months; marijuana, illicit substances (crack, cocaine, heroin, and
street methadone), erectile dysfunction drugs (while high, partying,
or drunk), or stimulant use in the past three months; and HIV
clinical parameters for participants who were HIV-positive
(months since tested HIV-positive, taking ARV therapy, selfreported CD4+ cell count, and undetectability of HIV viral load).
Data collection for qualitative interviews. Data were
collected through semi-structured interviews conducted separately
but simultaneously with each partner from March through
September 2011. Interviews consisted of open-ended questions
designed to elicit information about PrEP knowledge and
acceptability. PrEP was defined as ‘‘HIV-negative people taking
HIV medications to try to reduce their chances of becoming
infected with HIV.’’ Participants were asked to describe: 1) what
they had heard about PrEP, 2) how they had learned about PrEP,
3) personal experiences they may have had using PrEP themselves
or with their partner using PrEP, 4) their discussions with their
partner about PrEP, and 5) their thoughts on whether PrEP should
be offered to the community at large and potential issues that
should be considered in offering PrEP to the community.

Methods
Design
This mixed-methods study draws on data from serodiscordant
(HIV-positive/HIV-negative) and seroconcordant (HIV-positive/
HIV-positive) male couples of the Duo Project, a longitudinal
mixed-methods study of how relationship dynamics influence
ARV adherence [16,17].
In the quantitative survey of the Duo Project, we inquired about
participants’ PrEP knowledge, potential future PrEP uptake by the
HIV-negative member of the couple, and level of agreement with
the approach of offering PrEP to anyone who requests it. The
qualitative interview guide of the Duo Project included a
subsection of questions about participants’ knowledge of and
experiences with PrEP and concerns regarding health care
providers offering PrEP to the community.

Participants
Eligible participants were men who were 18 years or older,
provided written informed consent, had been in a primary
relationship for a minimum of three months, and at least one of
the men had to be HIV-positive and taking ARV medications for
at least 30 days. Those who showed signs of severe cognitive
impairment or active psychosis were excluded. Couples were
recruited from the San Francisco Bay Area using referrals from
participants and passive recruitment for which advertisements
were posted on community bulletin boards, clinic waiting rooms,
and at community-based organizations. Couples who called the
study telephone number were screened separately to confirm
eligibility and eligible couples were scheduled for an interview.
The qualitative interviews employed a purposeful sampling
strategy [18]. Following participants’ 12-month assessment in the
Duo Project, couples were systematically selected to participate in
a qualitative interview based on adherence reports at their 12month visit. Consistent with the overarching goals of the Duo
Project, our qualitative sampling strategy allowed us to compare
seroconcordant (HIV-positive/HIV-positive) and serodiscordant
couples with different levels of adherence.
The University of California, San Francisco Committee on
Human Research granted approval of this research and participants signed an informed consent form prior to initiation of study
procedures.
PLOS ONE | www.plosone.org

Analysis
Quantitative analysis. We used descriptive statistics to
generate frequencies for categorical variables and means and
standard deviations for continuous variables.
Using bivariable linear regression, we examined the association
between the three key PrEP questions (i.e., PrEP1-PrEP3) as
2
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in the past three months and 5% reported UIAI with someone
other than their primary partner who was HIV-negative/
serostatus-unknown. Among the HIV-negative men, 13% reported unprotected receptive anal intercourse (URAI) with their HIVpositive primary partner and 3% reported URAI with men other
than their primary partner who were HIV-positive/serostatusunknown.
As shown in Table 3, there were no statistically significant
differences between HIV-positive and -negative participants’
responses to PrEP questions. Over 62% of all participants had
heard about PrEP; predominantly through news articles and
websites. A total of ten participants reported having ever taken
PrEP to prevent HIV. Approximately one-third of respondents
had thought of taking PrEP for themselves or that their partner
should take PrEP. On a scale of zero to nine, representing ‘‘not at
all likely’’ to ‘‘extremely likely’’ to take PrEP in the future,
participants indicated a below average endorsement of PrEP
uptake for their partners (mean = 3.3) or themselves (mean = 3.9).
Lastly, participants most frequently expressed uncertainty about
whether PrEP should be offered to anyone who requests it (40%);
however, about 48% cumulatively endorsed ‘‘agree’’ or ‘‘strongly
agree’’, suggesting that some participants were open to the idea of
PrEP being made more available.
Bivariable linear regression results. Table 4 summarizes
p-values of all covariates that were examined in relation to the
three key PrEP outcome variables (i.e., PrEP1, PrEP2, and
PrEP3). Variables with a p-value,0.25 are bolded and were
examined in multivariable regression models.
Multivariable linear regression results. Model 1 examined correlates of HIV-positive men reporting the likelihood of
their HIV-negative partner taking PrEP in the future (i.e., PrEP1).
In this analysis, the HIV-positive individuals’ younger age
(B = 20.10; 95% confidence interval [CI] = 20.16, 20.03;
p = 0.003), lower level of education (B for high school graduate = 23.60, p = 0.23; B for some college = -5.13, p = 0.09; B for
college graduate or higher = 26.00, p = 0.04; overall p = 0.03), any
URAI with their HIV-negative primary partner (B = 3.02; 95%
CI = 0.26, 5.77; p = 0.03), and not being on ARVs (B = 23.58;
95% CI = 25.61, 21.56; p = 0.001) had statistically significant
associations with HIV-positive participants in serodiscordant
relationships reporting that their partner has a higher likelihood
of taking PrEP in the future.
Model 2 assessed correlates of HIV-negative men’s report of
their own likelihood of taking PrEP in the future (i.e., PrEP2). In
this model, having UIAI with their HIV-positive primary partner
(B = 2.15; 95% CI = 0.37, 3.93; p = 0.02) and not having URAI
with HIV-positive/serostatus-unknown men other than their
primary partner (B = 23.52; 95% CI = 24.40, 22.63; p,0.001)
were significantly associated with HIV-negative men’s higher
likelihood of taking PrEP in the future.
In the final model (Model 3), examining the level of agreement
with making PrEP widely available, younger age (B = 20.01; 95%
CI = 20.02, 20.0003; p = 0.045) and any URAI with men other
than primary partner (B = 0.62; 95% CI = 0.33, 0.90; p,0.0001)
had statistically significant associations with endorsement of the
statement that PrEP should be offered to anyone who requests it.
When Model 3 was refitted to each serostatus groups separately,
statistically significant results only emerged in the HIV-positive
sub-group.

outcome variables and covariates of interest such as demographics;
sexual behavior; marijuana, illicit substances, erectile dysfunction
drugs, or stimulant use; CES-D score; length of time together as a
couple; and HIV parameters for HIV-positive participants
(months since tested HIV-positive and taking ARVs). All
covariates with a p-value,0.25 in the bivariable models were
placed in three multivariable linear regression models (Models 1–
3), corresponding to the three key PrEP questions [19]. Using
backward elimination, variables were removed until all remaining
variables had a p-value,0.05. Model assumptions were assessed
by fitting restricted cubic splines for each continuous covariate and
performing a Wald test of spline terms 2 through k to assess for
linearity of the relationship of continuous covariates with each
outcome [20] and normality was checked by examining
histograms of residuals. Interactions were assessed by fitting all
possible first-order interactions in multivariable models at
alpha = 0.05 as a preliminary step prior to finalizing each model.
For Models 1 and 2, the HC3 heteroskedastic consistent estimator
was used to minimize model assumption violations. Due to nesting
of individuals within dyads in Model 3, we used robust HuberWhite standard errors, clustering on the couple ID. For all
regression analyses, we report the unstandardized regression
coefficient B and its associated p-value. A two-sided p-value,0.05
was considered statistically significant for variables included in the
final models. All analyses were conducted using Stata, version 11
(StataCorp, College Station, TX).
Qualitative analysis. We employed an inductive approach
[21] to gain a deeper understanding of participants’ awareness of
and experiences with PrEP and their concerns regarding health
care providers offering PrEP to members of their community. This
approach entails ‘‘detailed readings of raw data to derive concepts,
themes, or a model’’[21]. The interview segments in which
participants discussed PrEP were transcribed verbatim and
summarized and discussed in detail by the first and second
authors (PS and KG). Broad themes were then identified
individually by the first and second authors, refined through
discussion from the fourth author (MC), and entered into a matrix
using Microsoft Excel where each column corresponded to a
theme and each row represented a case. This method facilitated
data analysis and allowed for the identification of patterns in the
distribution of themes [22]. The first and second authors
independently categorized each interview using this matrix
(inter-rater reliability = 0.88) and coding discrepancies were
discussed by the two authors until consensus was reached or
arbitrated by the fourth author. Due to the nature of the
qualitative study as being nested in the Duo Project, achieving
data saturation was not an objective of the qualitative analysis.
Rather, we focused on the exploratory goal of eliciting information
from the Duo Project participants about their knowledge of,
experiences with, and thoughts about using PrEP in their own
relationships and concerns about health care providers offering
PrEP to the community at large.

Results
Quantitative results
Demographics. The sample comprised 164 couples (69
serodiscordant and 95 seroconcordant), 259 members of which
were HIV-positive and 69 HIV-negative (Table 1). Table 2
summarizes data regarding participants’ sexual behavior and drug
use in the past three months. With regards to HIV transmission
risk behavior, approximately 16% of HIV-positive men in
serodiscordant relationships reported having unprotected insertive
anal intercourse (UIAI) with their HIV-negative primary partner
PLOS ONE | www.plosone.org

Qualitative results
Demographics. We interviewed 16 couples (six serodiscordant), comprising 32 men which had a mean age of 48.1 years
(SD = 9.7), were 25.0% Black and 53.1% White, and 87.5% self3
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Table 1. Sample characteristics.

Age, mean (SD)

HIV+
(n = 259)

HIV2
(n = 69)

Total
(n = 328)

45.9 (9.4)

44.5 (11.2)

45.6 (9.8)

Race, n (%)
42 (16.2)

8 (11.6)

50 (15.2)

White/Caucasian

152 (58.7)

48 (69.6)

200 (61.0)

Other

65 (25.1)

13 (18.8)

78 (23.8)

45 (17.4)

9 (13.0)

54 (16.5)

Sexual orientation, n (%)

0.39
0.43

Homosexual

189 (73.0)

47 (68.1)

236 (72.0)

Bisexual/Other/Not sure

70 (27.0)

22 (31.9)

92 (28.1)

,High school

9 (3.5)

1 (1.5)

10 (3.1)

High school

63 (24.3)

16 (23.2)

79 (24.1)

Some college

74 (28.6)

13 (18.8)

87 (26.5)

College grad. or higher

113 (43.6)

39 (56.5)

152 (46.3)

45 (18.4)

10 (15.2)

55 (17.7)

Education, n (%)

0.20

Income, n (%)*
,$10, 000

0.30
0.26

Black/African American

Latino ethnicity, n (%)

p-value

0.16

$10,000–19,999

72 (29.4)

13 (19.7)

85 (27.3)

$$20,000

128 (52.2)

43 (65.2)

171 (55.0)

CES-D depression score, mean (SD)

14.7 (11.2)

14.1 (11.8)

14.6 (11.3)

0.52

Months as a couple, mean (SD)

79.9 (77.2)

79.9 (87.2)

79.9 (79.2)

0.63

Months since tested HIV-positive, mean (SD)

169.4 (97.8)

-

-

-

On antiretroviral medications, n (%)

245 (94.6)

-

-

-

CD4+ cell count, mean (SD)1,2

564.7 (248.8)

-

-

-

Undetectable HIV viral load, n (%)2

29 (11.2)

-

-

-

*The total of some categorical variables will not sum to the total number of participants in each column due to missing data.
CES-D: Center for Epidemiologic Studies Depression scale; SD: standard deviation.
1
n = 255; 2 Self-report.
doi:10.1371/journal.pone.0050061.t001

HIV infection, and complacency in talking to partners about HIV
risks.

identified as homosexual. Couples had been in a relationship
together for a mean duration of 100 months (SD = 68.6),
approximately 9% had not received a high school diploma, and
15.6% had an income less than $10,000 per year. A total of 25
individuals (78.1%) were HIV-positive, of which 88% were on
ARVs.
Themes. Approximately 81% of the participants stated that
they had heard about PrEP; however, examination of the
narratives revealed that 27% of these individuals were mistaking
PrEP for post-exposure prophylaxis (PEP). One participant
referred to PrEP as the ‘‘oops, morning-after pill.’’ Four
individuals had personal experiences with PrEP, by either
participating or knowing someone who was enrolled in a PrEP
trial.
Six prominent themes regarding concerns about offering PrEP
to the community at large emerged: 1) increased risky behavior or
risk compensation (discussed in 28% of interviews), 2) expense and
financial coverage of PrEP medications (19%), 3) ARV toxicity
and adverse effects (16%), 4) need for more public education
(13%), 5) need for more research on PrEP efficacy and behavioral
aspects (9%), and 6) drug resistance (9%).
The most frequently stated concern was the likelihood for
increased risky behavior. Participants discussed issues related to
potential reduction in condom use, decrease in worries related to

PLOS ONE | www.plosone.org

‘‘Everyone’s going to have unsafe sex if they think they can
prevent it because nobody wants to feel a condom; it’s no
fun… Common sense human nature would say ‘no condom,
take the PrEP’.’’ (age 61, White, HIV-positive, seroconcordant relationship).
‘‘It creates this idea, this way of absolving people of taking
necessary precautions like using condoms or wanting to
know something about their partners.’’ (age 35, Black, HIVpositive, serodiscordant relationship).
‘‘I’m terrified that people, instead of taking this drug because
they’re taking risk would feel more comfortable taking risks
because they have the drug. I’m worried about whether it
would increase or decrease the instances of HIV infection.’’
(age 49, White, HIV-negative, serodiscordant relationship).
‘‘It will be this open door that people can have unsafe sex…
people think that it [HIV]’s not a disease that kills people
anymore.’’ (age 38, White, HIV-positive, seroconcordant
relationship).

4
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Table 2. Sexual and substance use behavior.

HIV+
(n = 259)

HIV2
(n = 69)

Total
(n = 328)

p-value
0.05

*

Any UIAI with primary partner in past 3 months, n (%)

80 (30.9)

13 (18.8)

93 (28.4)

Any URAI with primary partner in past 3 months, n (%)

77 (29.7)

9 (13.0)

86 (26.2)

0.005

Any UIAI with men other than primary partner in past 3 months, n (%)

60 (23.2)

15 (21.7)

75 (22.9)

0.80
0.27

Number of other men with whom had UIAI in past 3 months, mean (SD)1

4.6 (5.6)

2.8 (2.8)

4.2 (5.2)

51 (19.7)

4 (5.8)

55 (16.8)

0.006

4.3 (7.0)

1.8 (1.0)

4.1 (6.7)

0.17

13 (5.0)

11 (15.9)

24 (7.3)

0.002

Number of HIV discordant/unknown other men with whom had UIAI in
past 3 months, mean (SD)3

2.8 (2.6)

3.1 (2.5)

3.0 (2.5)

0.43

Any URAI with HIV discordant/unknown men other than primary partner in
past 3 months, n (%)

23 (8.9)

2 (2.9)

25 (7.6)

0.10

2.4 (3.2)

2.5 (0.7)

2.4 (3.0)

0.17

Marijuana use in past 3 months, n (%)

148 (57.1)

39 (56.5)

187 (57.0)

0.93

Illicit substance use in past 3 months, n (%)5

30 (11.6)

12 (17.4)

42 (12.8)

0.20

Any URAI with men other than primary partner in past 3 months, n (%)
Number of other men with whom had URAI in past 3 months, mean (SD)2
Any UIAI with HIV discordant/unknown men other than primary partner in
past 3 months, n (%)

Number of HIV discordant/unknown other men with whom had URAI in
past 3 months, mean (SD)4

6

Erectile dysfunction drug use in past 3 months, n (%)

46 (17.8)

5 (7.3)

51 (15.6)

0.03

Stimulant use in past 3 months, n (%)

53 (20.5)

12 (17.4)

65 (19.8)

0.57

SD: standard deviation; UIAI: unprotected insertive anal intercourse; URAI: unprotected receptive anal intercourse.
*16% of HIV-positive men in serodiscordant relationships reported UIAI with their HIV-negative primary partner in the past three months.
1
n = 75; 2 n = 55; 3 n = 24; 4 n = 25.
5
Illicit substances: heroin, street methadone, crack, cocaine.
6
Erectile dysfunction drug use while high, partying, or drunk.
doi:10.1371/journal.pone.0050061.t002

Among those who brought up financial issues of PrEP, most
worried about the entity that would be required to pay for the
medications when they became available.

have no choice.’’ (age 45, Latino, HIV-positive, serodiscordant relationship).
The need for more public education was brought up numerous
times. This education included basic introduction of the existence
and uses of PrEP, as well as the need for continued safer sex
counseling.

‘‘If you’re a really wealthy guy… who works for an
investment bank, you’ll be fine; but from a practical
standpoint… it’s not economically feasible or practical;
especially given that funding is getting cut.’’ (age 47, White,
HIV-positive, serodiscordant relationship).

‘‘The only thing that I’d want to make sure of is the
education behind sexual practices because another hot thing
out there… [is] where these guys now think that people can
get on meds and live a long time, they go out and have a lot
of unprotected sex which is really sad but no one really
knows what it’s like until you’re positive… PrEP is a good
thing and it is like preventative medicine but there has to be
a message of ‘the best practice is still safe sex’.’’ (age 38,
White, HIV-positive, seroconcordant relationship).

Those who mentioned issues surrounding ARV adverse effects
were all HIV-positive and taking ARVs. These interviews reflected
a perception that the potential toxicities associated with ARVs
outweighed the possible benefits of PrEP.
‘‘[PrEP is] not a great idea because these drugs are not super
easy on the body, so from a physical standpoint I think
anybody would want to not take medications versus take
medications… [ARVs] affect liver and affect the kidneys and
are full of harsh chemicals and are expensive for people and
insurance companies… if you have the option of not taking
medications versus take medications, it seems odd to me to
want to take medications.’’ (age 35, Black, HIV-positive,
serodiscordant relationship).
‘‘I would be sort of against it… because you can be safe with
condoms and do you really want to be putting drugs in your
body unless you really absolutely need it? There are still
questions about the long run effects of HIV meds… I think
about what can potentially happen to me down the line after
all these years of taking these meds but I have to take them, I
PLOS ONE | www.plosone.org

Several participants discussed the need for more research to
establish whether PrEP is, in fact, effective in HIV prevention.
One participant noted the importance of behavioral research to
examine the potential for increased risk disinhibition.
‘‘I think that it needs to be studied in terms of psychological
as well as medical effects to see whether it increases
incidence of unprotected anal intercourse.’’ (age 49, White,
HIV-negative, serodiscordant relationship).
A few HIV-positive participants noted concerns about the
potential for drug resistance from taking PrEP medications.
5
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Table 3. Response to PrEP questions.

‘‘Have you ever heard about HIV-people taking HIV medications to try to
reduce their chances of becoming HIV infected? You might have heard of
this as PrEP.’’, n (%)
‘‘Where did you hear about PrEP?’’, n (%)

HIV+
(n = 259)

HIV2
(n = 69)

Total
(n = 328)

p-value

161 (62.2)

45 (65.2)

206 (62.8)

0.64

70 (43.5)

22 (48.9)

92 (44.7)

*

0.97

News article or story
Website

37 (23.0)

10 (22.2)

47 (22.8)

Research study/study flier

33 (20.5)

8 (17.8)

41 (19.9)

Sex partner

11 (6.8)

3 (6.7)

14 (6.8)

Friend or family member

8 (5.0)

2 (4.4)

10 (4.9)

My doctor

2 (1.2)

0

2 (1.0)

‘‘Have you ever taken PrEP to try to prevent getting HIV?’’,
n (%) *

-

8 (17.8)

-

-

‘‘Before you tested HIV+, did you ever take PrEP to try to prevent HIV?’’,
n (%) *

2 (1.2)

-

-

-

38 (23.6)

8 (17.8)

46 (22.3)

0.41

4 (26.7)

-

-

-

‘‘Before he tested HIV+, did your partner ever take PrEP to try to prevent
HIV?’’, n (%) *

1 (3.6)

0

1 (2.8)

-

‘‘Have you ever thought about you or your partner taking PrEP to try to
prevent HIV?’’, n (%) *

18 (38.3)

11 (29.7)

29 (34.5)

0.41

‘‘Have you and your partner ever discussed the possibility of you or your
partner taking PrEP to try to prevent HIV?’’, n (%) *

9 (50)

4 (36.4)

13 (44.8)

0.47

PrEP1: ‘‘How likely is it that your partner would use PrEP in the future?’’,
mean (SD) 1,2

3.3 (3.1)

-

-

-

PrEP2: ‘‘How likely is it that you would use PrEP in the future?’’,
mean (SD) 1,3

-

3.9 (2.7)

‘‘Do you know anyone who has taken PrEP?’’, n (%)

*

‘‘Has your partner ever taken PrEP to try to prevent getting HIV?’’, n (%)

*

0.16

PrEP3: ‘‘How much do you agree/disagree with this statement: ‘PrEP
should be offered to anyone who wants to take it’’’, n (%) *
Strongly disagree

6 (3.7)

1 (2.2)

Disagree

10 (6.2)

8 (17.8)

7 (3.4)
18 (8.7)

Uncertain

64 (39.8)

18 (40.0)

82 (39.8)

Agree

49 (30.4)

12 (26.7)

61 (29.6)

Strongly agree

32 (19.9)

6 (13.3)

38 (18.5)

*The total of some categorical variables will not sum to the total number of participants in each column due to missing data.
SD: Standard deviation.
1
Scale from 0 = ‘‘not at all’’ to 9 = ‘‘extremely likely’’.
2
n = 52.
3
n = 45.
doi:10.1371/journal.pone.0050061.t003

people’’ (age 49, Black, HIV-positive, seroconcordant
relationship).
‘‘I guess the ideal thing would be to find out what the
person’s personal habits are already… if someone is
regularly using condoms and taking care to not get HIV,
they’re probably not the best candidate to sell this to because
it may get them off the condoms; but if it is somebody that is
going to bathhouses every weekend and they are HIVnegative, they should definitely have the option… my
concern is that people that aren’t at high risk may start to
engage in more risky behavior’’ (age 44, White, HIVpositive, seroconcordant relationship).
‘‘I’d be concerned [that] some people would think that it
would mean that it would be okay to have any kind of
risky… high risk behavior… on the other hand… if you are

‘‘If you take things like… [PrEP] too early, you build up a
tolerance or resistance and later on when you might really
need it…’’ (age 62, White, HIV-positive, serodiscordant
relationship).
Several participants offered specific options for the provision of
PrEP by health care providers. Six individuals stated that PrEP
should be limited to those at highest risk, such as young HIVnegative MSM or those who are not using condoms. The exclusive
use of PrEP in serodiscordant couples was another option
discussed by three participants.
‘‘It should be offered to those who are sexually active at
younger ages… but only if they’re having sex with a lot of

PLOS ONE | www.plosone.org
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Table 4. Bivariable analysis p-values.

PrEP1
(n = 51)

PrEP2
(n = 45)

PrEP3
(n = 206)

Age

0.005

0.74

0.02

Race

0.33

0.64

0.85

White/Caucasian

ref

ref

ref

Black/African American

0.33

0.92

0.73

Other

0.22

0.35

0.69

Latino ethnicity

0.17

0.88

0.75

Sexual orientation

-

-

ref

Homosexual

ref

ref

Bisexual/Other/Not sure

0.35

0.91

0.17

0.08

0.74

0.95

Education
,High school

ref

ref

ref

High school

0.29

0.33

0.77

Some college

0.25

0.36

0.75

College grad. or higher

0.11

0.45

0.69

Income

0.58

,$10, 000

ref

a

0.40

b

ref

0.42

c

ref

$10,000–19,999

0.73

0.20

0.20

$$20,000

0.37

0.55

0.47

CES-D depression score

0.26

0.87

0.55

Months as a couple

0.48

0.74

0.44

Any UIAI with primary partner in past 3 months

0.13

0.01

0.11

Any URAI with primary partner in past 3 months

0.10

0.94

0.62

Any UIAI with men other than primary partner in past 3 months

0.44

0.90

0.05

Any URAI with men other than primary partner in past 3 months

0.27

0.41

,0.001

Any UIAI with HIV discordant/unknown men other than primary partner in past 3 months

0.93

0.80

0.11

Any URAI with HIV discordant/unknown men other than primary partner in past 3 months

0.66

,0.001

0.002

Marijuana use in past 3 months

0.92

0.20

0.67

0.67

0.56

0.14

0.22

0.69

0.009

Stimulant use in past 3 months

0.61

0.87

0.26

Months since tested HIV-positive

0.29

-

0.94

d

On ARVs

0.19

-

0.86

d

Illicit substance use in past 3 months

e

Erectile dysfunction drug use in past 3 months

f

a

n = 48; b n = 43; c n = 199; d n = 161.
Illicit substances: heroin, street methadone, crack, cocaine.
f
Erectile dysfunction drug use while high, partying, or drunk.
ARV: antiretroviral; CES-D: Center for Epidemiologic Studies Depression scale; Ref: reference variable; UIAI: unprotected insertive anal intercourse; URAI: unprotected
receptive anal intercourse.
PrEP1: ‘‘How likely is it that your partner would use PrEP in the future?’’ (0: not at all to 9: extremely): asked of all participants with an HIV-negative partner.
PrEP2: ‘‘How likely is it that you would use PrEP in the future?’’ (0: not at all –9: extremely): asked of all HIV-negative participants.
PrEP3: ‘‘How much do you agree or disagree with the following statement: ‘PrEP should be offered to anyone who wants to take it.’’’ (1: strongly disagree –5: strongly
agree): asked of all participants.
doi:10.1371/journal.pone.0050061.t004
e

‘‘I’m glad that they are coming up with ways to prevent HIV
infection but there if a big need out there in the world for
HIV meds for people who do have it [HIV] so I’m kind of
skeptical about whether they should be giving it to people
who don’t have it yet.’’ (age 48, White, HIV-positive,
seroconcordant relationship).

in a relationship where you’re not in the same serostatus, it
has a certain appeal because we both have a little bit of
anxiety about when I get my every three-month HIV test…
a little anxiety about ‘maybe… what if?’ and it would be nice
if you could be less nervous about that.’’ (age 51, White,
HIV-negative, serodiscordant relationship).
Although most participants agreed that PrEP should be offered
to anyone who requests it, there were a few who were skeptical.
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unknown was negatively correlated with future PrEP use.
Therefore, if we were to consider sexual risk behavior on a
continuum, ranging from very low risk (no unprotected sex) to
maximum risk (HIV-negative men having URAI with HIVpositive men); PrEP seemed to have been most appealing to HIVnegative MSM who were engaged in a moderate level of risk but
not the highest risk. We hypothesize that this may have been due
to the fact that those who were mindful of their risk may have
already been engaging in low to moderate risk (i.e., seropositioning
by UIAI with HIV-positive primary partner) and may have been
more likely to want to further reduce their risk of HIV infection.
Conversely, those at the highest risk (i.e., HIV-negative men
reporting URAI with outside HIV-positive/unknown-serostatus
partners) may have been less likely to be aware of their actual level
of risk behavior or less concerned about becoming HIV infected.
These findings point to one of the major dilemmas of PrEP that
remains to be answered in future research: will the use of PrEP
shift those who are already mindful of their risk and attempting to
decrease their risk by strategies such as strategic positioning to a
higher risk category?
One theory behind futile results of the FEM-PrEP trial is that
the women who were included in this trial were at high risk of HIV
infection but approximately 70% considered themselves to be at
low risk or not at risk for HIV and thus this disconnect between
behavior and risk perception may have influenced PrEP adherence
[7]. Therefore, future research is needed to examine the efficacy of
PrEP in MSM engaged in various levels of sexual risk, as well as
their perception of HIV risk to determine the appropriate
populations where PrEP can have the highest impact and groups
in which more education and closer monitoring may be
warranted. This is of paramount importance because any increase
in risk behavior resulting from behavioral disinhibition among
those who are more aware of their potential for HIV infection and
currently engaged in low to moderate risk behavior could
counteract or reverse any benefits from PrEP.
In our quantitative survey, younger age, lower education, and
not being on ARVs were positively associated with HIV-positive
men’s beliefs that their partner would use PrEP and younger age
was similarly related to HIV-positive men’s level of agreement
with offering PrEP to the community. HIV-positive participants
on ARVs also raised concerns regarding PrEP toxicity and drug
resistance in qualitative interviews. Cumulatively, these data
indicate that those who were older, more educated, or on ARVs
may have had an increased awareness of long-term ARV risks, had
experienced adverse effects from taking older generations of ARV
medications for longer durations, had a better grasp of adherence
challenges and consequences of non-adherence in comparison to
HIV-positive men who were younger, less educated, or not on
ARVs. Although serious toxicities of tenofovir appear to occur
infrequently and the majority of the events associated with TDF/
FTC were mild or moderate in severity in the iPrEX study [2],
long-term consequences of PrEP on bone and kidney health of
HIV-negative individuals are unknown [27,28]. Additionally, of
the subjects who became HIV-positive during the iPrEX trial, no
evidence of genotypic drug resistance was detected; however, very
few had detectable drug levels at the time of seroconversion.
Therefore, data from our study emphasize the importance of
education of HIV-positive members of the community on the
potential differences in the occurrence of adverse effects and drug
resistance among HIV-negative individuals on PrEP versus those
taking ARVs for HIV treatment in addition to the critical
importance of adherence.
Two proposals by our qualitative study participants for the
provision of PrEP by health care providers were to offer PrEP to

Discussion
Our findings suggest that approximately 62% of participants in
quantitative surveys and 81% of qualitative participants had heard
of PrEP; however, qualitative data suggest that it is likely that these
proportions are an overestimation and that about a quarter of
these individuals confused PrEP with PEP. Therefore, reports of
PrEP awareness among MSM may be overestimated and more
effective messaging is necessary to educate individuals about the
differences between PrEP and PEP.
In contrast to other studies [11,23], approximately 40% of men
and their partners in our quantitative study had low endorsement
of PrEP uptake in the future and were ambivalent as to whether
PrEP should be offered widely. Qualitative data indicate that this
uncertainty was due to concerns about increased risk compensation, costs associated with PrEP medications, ARV adverse effects,
the need for more public education and research, and potential for
drug resistance. In contrast, roughly 48% of participants agreed or
strongly agreed with the idea that PrEP should be offered to
anyone who requests it. This high level of support may indicate the
need for increased PrEP access, public education, and training of
health care providers in appropriately prescribing PrEP, providing
counseling and safer sex education, and monitoring for PrEP
adverse effects or HIV seroconversion.
Behavioral disinhibition or risk compensation was the most
frequently stated apprehension with the availability of PrEP. These
concerns have been echoed in other publications [23,24,25,26]
and various models have suggested that small increases in risk
behavior could potentially offset or reverse PrEP’s benefits in
reducing HIV infections at the population level [13,14]. This
concern is in contrast to the findings of the iPrEx study, which
revealed a decrease in sex partners and an increase in condom use
in both study arms [2]. However, in this trial, in addition to
receiving frequent comprehensive counseling on the importance of
condom use, participants were educated about the unproven
efficacy of the active drug and the fact that they may be taking
placebo. Therefore, it is difficult to discern whether risk
compensation will arise with the introduction of PrEP and, as
also voiced by our study participants, further research on the
impact of PrEP on risk compensation and change in risk over time
is crucial. In the absence of data on the real-world impact of PrEP
on sexual risk behavior, frequent risk reduction counseling and
discussion about sex practices is an essential part of PrEP delivery
in a clinical setting.
It is notable that when asked about PrEP, participants focused
primarily on troubling factors such as risk compensation, costs,
and potential negative long-term health consequences, rather than
possible positive aspects of PrEP, such as increased sexual
enjoyment or intimacy that may accompany reduced condom
use. Their cautionary words and occasionally moralistic statements
may suggest that for men who cope with HIV on a daily basis, the
potential renegotiation of sexual safety strategies trigger concerns
and fears, perhaps due to a highly informed understanding of what
HIV infection and its treatment entail. The tendency to express
worry and doubt about PrEP may also be due to the participants’
relatively older age, having lived through a havoc wreaked by
AIDS in the 1980s and early 1990s. Their perception may have
been that younger men who did not endure those years may hold
cavalier views on PrEP.
A surprising finding among HIV-negative participants in our
quantitative study was that those who reported UIAI with their
HIV-positive primary partner were more likely to report possible
future uptake of PrEP; however, the report of URAI with men
other than primary partner who were HIV-positive/serostatusPLOS ONE | www.plosone.org
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those who are already engaged in high risk behavior and to those
in serodiscordant relationships. The use of PrEP in HIV
serodiscordant couples resulted in a 67-75% HIV risk reduction
in the Partners PrEP study and is likely to be an important factor
in the selection of appropriate candidates for PrEP use [3]. The
prioritization of PrEP among MSM engaged in URAI has also
been raised by other investigators [29]; however, the feasibility of
identifying ideal ‘‘PrEP candidates’’ in a clinical setting and the
efficacy of PrEP in these individuals, as well as the capacity of
health care providers to monitor adverse effects and adherence
[30] remains to be determined.
We used a mixed-methods approach to study knowledge,
concerns, and correlates of future PrEP use in MSM living in San
Francisco. This approach allowed us to complement our
quantitative surveys with in-depth narratives from the qualitative
interviews and to further explore participants’ PrEP knowledge
and concerns. A strength of this study is the utilization of couplesbased data. Serodiscordant couples represent a potential target
group for the implementation of PrEP and men in seroconcordant
HIV-positive relationships may have outside partners or future
primary partners who are HIV-negative. Therefore, understanding these individuals’ level of awareness, attitudes, and concerns
towards PrEP are important to assess and can contribute to better
tailored messages and programs.
The design of the parent trial (i.e., the Duo Project) in which the
qualitative interviews and quantitative survey were nested, limited
our ability to utilize an iterative and integrated process between
these two study arms. This parent trial also dictated the sampling
for the two studies, in which the qualitative interviews had a
slightly older population. Due to a certain level of confusion
between PrEP and PEP, we do not know if our results would have
been different had this confusion not existed. Ultimately, this
confusion underscores the need for more education about HIV
prevention approaches and the need for future research to clearly
differentiate between these concepts. The goal of this study was

primarily formative and exploratory; therefore, the uncovered
themes and survey results may not be generalizable and
representative of the entire MSM community in San Francisco
or other cities worldwide.
Our findings have important implications for developing PrEP
interventions as the effectiveness of PrEP will depend on the
community’s understanding of what PrEP is and their willingness
to accept it as part of an HIV prevention strategy. Our data reveal
the need for more intense efforts to introduce, educate, and gather
feedback from MSM communities on the use, efficacy, cost, and
toxicity of PrEP. This need also parallels the necessity to further
train health care providers who will likely be the spokespersons for
PrEP use in clinical settings. The appropriate use of PrEP in HIVnegative individuals and early initiation of ARVs in those living
with HIV [31] have the potential to dramatically reduce HIV
incidence. Our study findings suggest that there is much ambiguity
about PrEP, ambivalence regarding future PrEP use, and
apprehensions concerning the impact of PrEP on risk behavior.
We believe that a comprehensive effort to educate, provide clinical
care, and conduct clinical research is needed to overcome these
issues.
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